<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349270</url>
  </required_header>
  <id_info>
    <org_study_id>0201084</org_study_id>
    <secondary_id>031213</secondary_id>
    <nct_id>NCT01349270</nct_id>
  </id_info>
  <brief_title>Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg</brief_title>
  <acronym>PRNC</acronym>
  <official_title>Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a challenge because&#xD;
      disease may generate important disability in patients including young adults. Randomized&#xD;
      trials showed that corticosteroids, plasma exchanges and intravenous immunoglobulin (IVIg)&#xD;
      can reduce impairment on a short term period but the treatment of a chronic disease doesn't&#xD;
      agree with it. Corticosteroids and IVIg are the first line CIDP treatments. No study permits&#xD;
      to demonstrate the superiority of one treatment to the other. Long term adverse effects of&#xD;
      corticosteroids and IVIg cost are the respective limitation of their use. The investigators&#xD;
      scheduled to recruit 40 CIDP patients in 23 French centres to receive either 0,8mg/kg/day of&#xD;
      prednisone progressively tapered over 6 months or a monthly 2g/kg cure of IVIg during 6&#xD;
      months. Patients will be followed during 6 months after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of patients with a decreased INCAT score of at least 1 point after 3 months of treatment,&#xD;
Responders: ≥ 1 point improvement in the INCAT score at 3 months in comparison to baseline,&#xD;
Non responders: unchanged INCAT score at 3 months in comparison to baseline or patients for whom the primary endpoint can't be assessed because of the occurrence of an adverse event requiring treatment stop.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of cured patients i.e. INCAT score of 0 in legs and ≤ 1 in arms after 3, 6, 9 and 12 months,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Demyelinating Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulin perfusion</intervention_name>
    <description>patient who received monthly 2g/kg intravenous cure of immunoglobulin</description>
    <arm_group_label>immunoglobulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months</description>
    <arm_group_label>prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman between 18 and 80, Weight ≤ 100 kg,&#xD;
&#xD;
        CIDP diagnosis:&#xD;
&#xD;
          -  stable or deteriorated state (no spontaneous improvement),&#xD;
&#xD;
          -  with the following features:&#xD;
&#xD;
          -  motor or sensory and motor deficits, and reduced or abolished tendon reflexes,&#xD;
&#xD;
          -  progressive or relapsing evolution,&#xD;
&#xD;
          -  global symmetric disability in more than one limb,&#xD;
&#xD;
          -  disease course installation over at least 2 months,&#xD;
&#xD;
          -  cerebrospinal fluid with ≤10/µL white blood cells and &gt; 0.5 g/L protein rate (non&#xD;
             compulsory examination),&#xD;
&#xD;
          -  electrophysiological or histological signs of demyelinization,&#xD;
&#xD;
          -  INCAT disability score ≥ 2 in arms or ≥ 1 in legs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe electrophysiological axonal damage,&#xD;
&#xD;
          -  Pure motor syndrome,&#xD;
&#xD;
          -  Spontaneous improvement,&#xD;
&#xD;
          -  Associated systemic disease that could be the cause of neuropathy,&#xD;
&#xD;
          -  Severe cardiac insufficiency,&#xD;
&#xD;
          -  Cardiac arrhythmia,&#xD;
&#xD;
          -  Severe cardiopulmonary pathology,&#xD;
&#xD;
          -  Inflammatory syndrome,&#xD;
&#xD;
          -  Severe physical disease which can interfere with the trial,&#xD;
&#xD;
          -  Patient in a strict salt-free diet,&#xD;
&#xD;
          -  A clinically significant abnormal biological result,&#xD;
&#xD;
          -  Positive serology in one of the following tests: HIV1, HIV2, A-B-C hepatitis, Hbs&#xD;
             antigen, Lyme disease,&#xD;
&#xD;
          -  IgA complete deficiency,&#xD;
&#xD;
          -  History of anaphylactic reaction during previous IVIg infusion,&#xD;
&#xD;
          -  Hypogammaglobulinemia (IgG &lt; 3g/L),&#xD;
&#xD;
          -  Creatinine clearance &lt; 80 mL/min,&#xD;
&#xD;
          -  Evolutive gastroduodenal ulcer, diabetes, serious infectious condition, evolutive&#xD;
             virus disease (hepatite, herpes, varicella, zona), psychotic states not controlled by&#xD;
             treatment, veinous or arterial thrombosis, non controlled high blood pressure,&#xD;
             osteoporosis,&#xD;
&#xD;
          -  Patient previously treated by corticosteroids, IVIg, plasma exchanges or any other&#xD;
             immunosuppressive agent within 3 months before inclusion, except for azathioprine and&#xD;
             mycophenolate mofetil which were tolerated in the case of the dose being unmodified&#xD;
             within 3 months and kept unchanged during the trial,&#xD;
&#xD;
          -  Experienced failure with a IVIG or prednisone prior treatment,&#xD;
&#xD;
          -  Hypersensitivity to any components of the 2 treatments,&#xD;
&#xD;
          -  Unsigned informed consent,&#xD;
&#xD;
          -  Ongoing or planned pregnancy (mandatory pregnancy test at the screening visit),&#xD;
             breastfeeding, effective contraception for over 3 months for women of childbearing&#xD;
             age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe CAMDESSANCHE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Valence</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic inflammatory demyelinating polyneuropathy</keyword>
  <keyword>immunoglobulin</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

